Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 199-209 , June 2003

Immunotherapy and prostate cancer

  • Joseph M Kaminski

      Affiliations

    • Department of Radiology, Medical College of Georgia, Augusta, GA 30912, USA
    • ,
  • James B Summers

      Affiliations

    • Department of Diagnostic Radiology, University of South Alabama, Mobile, AL 36617, USA
    • Corresponding Author InformationCorrespondence to: James B. Summers, MD, MS, Department of Radiology, University of South Alabama Hospitals, Mobile, AL 36616, USA. Tel.: 1-251-639-3431; Fax: 1-251-471-7882
    • ,
  • Matthew B Ward

      Affiliations

    • Department of Radiology, University of Chicago Hospitals, Chicago, IL 60637, USA
    • ,
  • Mark R Huber

      Affiliations

    • Department of Internal Medicine, Rochester, MN 55905, USA
    • ,
  • Boris Minev

      Affiliations

    • UCSD Cancer Center, University of California, La Jolla, CA 92093-0658, USA

References 

  1. Boon T. Teaching the immune system to fight cancer. Sci. Am. 1993;268:82–89
  2. Restifo N. Antigen processing and presentation: an update. In:  DeVita VT,  Hellman S,  Rosenberg SA editor. Biologic Therapy of Cancer Updates. vol. 2, No. 2:Philadelphia: Lippincott Healthcare Publications; 1992;p. 1–10
  3. Klein G, Sjorgren HO, Klein E, Hellstrom KE. Demonstration of resistance against methylcholanthrene-induced sarcomas in the primary autochthonous host. Cancer Res. 1960;20:1561–1572
  4. Prehn RT, Main JM. Immunity to methylcholanthrene-induced sarcomas. J. Natl. Cancer Inst. 1957;18:769–778
  5. Townsend AR, Rothbard J, Gotch FM, et al.  The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell. 1986;44:959–968
  6. Bjorkman PJ, Saper MA, Samraoui B, et al.  The foreign antigen binding site and T-cell recognition regions of class I histocompatibility antigens. Nature. 1987;329:512–518
  7. van der Bruggen P, Traversari C, Chomez P, et al.  A gene encoding an antigen recognized by cytotoxic T-lymphocytes on human melanoma. Science. 1991;254:1643–1647
  8. Sercarz EE, Lehmann PV, Ametani A, et al.  Dominance and crypticity of T-cell antigenic determinants. Annu. Rev. Immunol. 1993;11:729–766
  9. Nanda NK, Sercarz EE. Induction of anti-self immunity to cure cancer. Cell. 1995;82:13–17
  10. Zheng P, Sarma S, Guo Y, Liu Y. Two mechanisms for tumor evasion of preexisting cytotoxic T-cell responses: lessons from recurrent tumors. Cancer Res. 1999;59:3461–3467
  11. Blades RA, Keating PJ, McWilliam LJ, George NJ, Stern PL. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology. 1995;46:681–686
  12. Seliger B, Maeurer MJ, Ferrone S. TAP off- tumors on. Immunol. Today. 1997;18:292–299
  13. Johnsen AK, Templeton DJ, Sy M, Harding CV. Deficiency of transporter for antigen presentation (TAP) in tumor cells allows evasion of immune surveillance and increase tumorigenesis. J. Immunol. 1999;163:4224–4231
  14. Restifo NP, Esquivel F, Kawakami Y, et al.  Identification of human cancers deficient in antigen processing. J. Exp. Med. 1993;177:265–272
  15. Restifo NP, Esquivel F, Asher AC, et al.  A defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J. Immunol. 1991;147:1453–1459
  16. Sanda MG, Restifo NP, Walsh JC, et al.  Molecular characterization of defective antigen processing in human prostate cancer. J. Natl. Cancer Inst. 1995;87:280–285
  17. Chen L, Ashe S, Brady WA, et al.  Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell. 1992;71:1093–1102
  18. Ramarathinam L, Castle M, Wu Y, Liu Y. T cell costimulation by B7/BB1 induces CD8 T cell-dependent tumor rejection: an important role of B7/BB1 in the induction, recruitment, and effector function of antitumor T cells. J. Exp. Med. 1994;179:1205–1214
  19. Wu TC, Huang AY, Jaffee EM, Levitsky HI, Pardoll DM. A reassessment of the role of B7-1 expression in tumor rejection. J. Exp. Med. 1995;182:1415–1421
  20. Strand S, Galle PR. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. Mol. Med. Today. 1998;4:63–68
  21. Strand S, Hoffmann WJ, Hug H, et al.  Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells – a mechanism of immune evasion?. Nat. Med. 1996;2:1361–1366
  22. Nagata S. Fas ligand and immune evasion. Nat. Med. 1996;2:1306–1307
  23. Zietz C, Rumpler U, Sturzl M, Lohrs U. Inverse relation of Fas-ligand and tumor-infiltrating lymphocytes in angiosarcoma: indications of apoptotic tumor counterattack. Am. J. Pathol. 2001;159:963–970
  24. Gross N, Balmas K, Beretta Brognara C, Tschopp J. Expression of Fas (APO-1/CD95) and Fas ligand (FasL) in human neuroblastoma. Med. Pediatr. Oncol. 2001;36:111–114
  25. Perabo FG, Kamp S, Schmidt D, et al.  Bladder cancer cells acquire competent mechanisms to escape Fas-mediated apoptosis and immune surveillance in the course of malignant transformation. Br. J. Cancer. 2001;84:1330–1338
  26. Shimonishi T, Isse K, Shibata F, et al.  Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiosarcoma reflect evasion from immune surveillance. Hepatology. 2000;32:761–769
  27. Okada K, Komuta K, Hashimoto S, Matsuzaki S, Kanematsu T, Koji T. Frequency of apoptosis of tumor-infiltrating lymphocytes induced by Fas counterattack in human colorectal carcinoma and its correlation with prognosis. Clin. Cancer Res. 2000;6:3560–3564
  28. Gastman BR, Atarshi Y, Reichert TE, et al.  Fas ligand is expressed on human squamous cell carcinoma of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res. 1999;59:5356–5364
  29. Gutierrez LS, Eliza M, Niven-Fairchild T, et al.  The Fas/Fas-ligand system: a mechanism for immune evasion in human breast carcinomas. Breast Cancer Res. Treat. 1999;54:245–253
  30. Mitsiades N, Poulaki V, Mastorakos G, et al.  Fas ligand expression in thyroid carcinomas: a potential mechanism of immune evasion. J. Clin. Endocrinol. Metab. 1999;84:2924–2932
  31. Kume T, Oshima K, Yamashita Y, et al.  Relationship between Fas-ligand expression on carcinoma cell and cytotoxic T-lymphocyte response in lymphoepithelioma-like cancer of the stomach. Int. J. Cancer. 1999;84:339–343
  32. O’Connell J, Bennett MW, O’Sullivan GC, et al.  Fas ligand expression in primary colon adenocarcinomas: evidence that the Fas counterattack is a prevalent mechanism of immune evasion in human colon cancer. J. Pathol. 1998;186:240–246
  33. Khar A, Varalakshmi C, Pardhasaradhi BV, et al.  Depletion of natural killer cell population in the peritoneum by AK-5 tumor cells overexpressing Fas-ligand: a mechanism of immune evasion. Cell Immunol. 1998;189:85–91
  34. Ali SA, Rees RC, Anderson DQ, et al.  Trafficking of immune CD4+/CD8+ T-lymphocytes into RENCA tumour microcirculation in vivo in mice. Br. J. Cancer. 2000;83:1061–1068
  35. Ali M, Lemoine NR, Ring CJ. The use of DNA viruses as vectors for gene therapy. Gene Ther. 1994;1:367–384
  36. Mulligan RC. The basic science of gene therapy. Science. 1993;260:926–932
  37. Palapattu GS, Naitoh J, Belldegrum AS. Gene therapy for prostate cancer. Urol Clin. North Am. 1999;26:353–363
  38. Yu DC, Chen Y, Seng M, Dilley J, Henderson DR. The addition of adenovirus type 5 region E3 enables Calydon Virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 1999;59:4200–4203
  39. Dannull J, Belldegrun AS. Development of gene therapy for prostate cancer using a novel promoter of prostate-specific antigen. Br. J. Urol. 1997;79:97–103
  40. Cowen D, Salem N, Ashoori F, et al.  Prostate cancer radiosensitization in vivo with adenovirus-mediated p53 gene therapy. Clin. Cancer Res. 2000;6:4402–4402
  41. Hamada K, Alemany R, Zhang WW, et al.  Adenovirus-mediated transfer of a wild-type p53 gene and induction of apoptosis in cervical cancer. Cancer Res. 1996;56:3047–3054
  42. Gomez-Manzano C, Fueyo J, Kyritsis AP, et al.  Adenovirus-mediated transfer of the p53 gene produces rapid and generalized death of human glioma cells via apoptosis. Cancer Res. 1996;56:694–699
  43. Kremer EJ, Perricaudet M. Adenovirus and adenoassociated virus mediated gene transfer. Br. Med. Bull. 1995;51:31–44
  44. Vieweg J, Boczkowski D, Roberson KM, et al.  Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 1995;55:2366–2372
  45. Hill TJ, Yirrell DL, Blyth WA. Infection of the adrenal gland as a route to the central nervous system after viraemia with herpes simplex virus in the mouse. J. Gen. Virol. 1986;67:309–320
  46. Irie H, Koyama H, Kubo H, et al.  Herpes simplex virus hepatitis in macrophage-depleted mice: the role of massive, apoptotic death in pathogenesis. J. Gen. Virol. 1998;79:1225–1231
  47. Latchman DS. Gene delivery and gene therapy with herpes simplex virus based vectors. Gene. 2001;264:1–9
  48. Rampling R, Cruickshank G, Papanastassiou V, et al.  Toxicity evaluation of replication-competent herpes simplex virus (ICP34.5 null mutant1716) in patients with recurrent malignant glioma. Gene Ther. 2000;7:859–866
  49. Walker JR, McGeagh KG, Sundaresan P, et al.  Local and systemic therapy of human prostate adenocarcinoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 1999;10:2237–2243
  50. Moss B. Vaccinia virus: a tool for research and vaccine development. Science. 1991;252:1662–1667
  51. Mastrangelo MJ, Berd D, Nathan FE, Lattime EC. Gene therapy for human cancer: an essay for clinicians. Semin Oncol. 1996;23:4–21
  52. Kawakita M, Rao GS, Ritchey JK, et al.  Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J. Natl. Cancer Inst. 1997;89:428–436
  53. Farhood H, Gao X, Son K, et al.  Cationic liposomes for direct gene transfer in therapy of cancer and other diseases. Ann. N. Y. Acad. Sci. 1994;716:23–34
  54. Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. Biochim. Biophys. Acta. 1995;1233:134–144
  55. Gottschalk S, Cristiano RJ, Smith LC, Woo SL. Folate receptor mediated DNA delivery into tumor cells: protosomal disruption results in enhanced gene expression. Gene Ther. 1994;1:185–191
  56. Boulikas T. Gene therapy of prostate cancer: p53, suicidal genes, and other targets. Anticancer Res. 1997;17:1471–1506
  57. Kaneda Y, Iwai K, Uchida T. Increased expression of DNA cointroduced with nuclear protein in adult rat liver. Science. 1989;243:375–378
  58. Izsvak Z, Ivics Z, Plasterk RH. Sleeping Beauty, a wide host-range transposon vector for genetic transformation in vertebrates. J. Mol. Biol. 2000;302:93–102
  59. Kaminski JM, Huber MR, Summers JB, Ward MB. Design of a nonviral vector for site-selective, efficient integration into the human genome. FASEB J. 2002;16:1242–1247
  60. Wheeler JJ, Palmer L, Ossanlou M, et al.  Stabilized plasmid-lipid particles: construction and characterization. Gene Ther. 1999;6:271–281
  61. Huang SK, Lee KD, Hong K, Friend DS, et al.  Microscopic localization of sterically stabilized liposomes in colon carcinoma-bearing mice. Cancer Res. 1992;52:5135–5143
  62. Huang SK, Martin FJ, Jay G, Vogel J, et al.  Extravasation and transcytosis of liposomes in Kaposi’s sarcoma-like dermal lesions of transgenic mice bearing the HIV tat gene. Am. J. Pathol. 1993;143:1–14
  63. Harrington KJ, Mohammadtaghi S, Uster PS, et al.  Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin. Cancer Res. 2001;7:243–254
  64. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979;17:159–163
  65. Watt KW, Lee PJ, M’Timkulu T, Chan WP, Loor R. Human prostate-specific antigen: structural and functional similarities with serine proteases. Proc. Natl. Acad. Sci. USA. 1986;83:3166–3170
  66. Lundwall A, Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett. 1987;214:317–322
  67. Correale P, Walmsley K, Nieroda C, et al.  In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen. J. Natl. Cancer Inst. 1989;4:293–300
  68. Xue BH, Zhang Y, Sosman JA, Peace DJ. Induction of human cytotoxic T lymphocytes specific for prostate-specific antigen. Prostate. 1997;30:73–78
  69. Harris DT, Matyas GR, Gomella LG, et al.  Immunologic approaches to the treatment of prostate cancer. Semin Oncol. 1999;26:439–447
  70. Gulley J, Chen AP, Dahut W, et al.  Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rv-PSA) in patients with metastatic androgen-independent prostate cancer. Prostate. 2002;53:109–117
  71. Israeli RS, Powell CT, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specific membrane antigen. Cancer Res. 1993;53:227–230
  72. Kawakami M, Nakayama J. Enhanced expression of prostate-specific membrane antigen gene in prostate cancer as revealed by in situ hybridization. Cancer Res. 1997;15:2321–2324
  73. Murphy G, Ragde H, Kenny G, et al.  Comparison of prostate-specific membrane antigen, and prostate specific antigen levels in prostate cancer patients. Anticancer Res. 1995;15:1473–1479
  74. Horoszewics JS, Kawinski E, Murphy GP. Monoclonal antibodies to a new antigenic marker in epithelial cells and serum of prostatic cancer patients. Anticancer Res. 1987;7:927–935
  75. Engelhard VH. Structure of peptides associated with class I and class II MHC molecules. Annu. Rev. Immunol. 1994;12:181–207
  76. Tjoa B, Boynton A, Kenny G, Ragde H, Misrock SL, Murphy G. Presentation of prostatic tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity. Prostate. 1996;28:65–69
  77. Tjoa BA, Lodge PA, Salgaller ML, Boynton AL, Murphy GP. Dendritic cell-based immunotherapy for prostate cancer. CA Cancer J. Clin. 1999;49:117–128
  78. Assikis VJ, Elgamal A, Tu S, et al. Immunotherapy for androgen independent prostate cancer: results of a phase I trial with a tumor vaccine of autologous dendritic cells loaded with r-PSMA (DCVaxTM-Prostate). 93rd Ann Meet AACR 2002;(Abstr):3352
  79. Kahn D, Austin JC, Maguire RT, et al.  A phase II study of [90 Y] ytrrium-capromab pendetide in the tratment of men with prostate cancer recurrence following radical prostatectomy. Cancer Biother Radiopharm. 1999;14:99–111
  80. McDevitt MR, Ma D, Lai LT, et al.  Tumor therapy with targeted atomic nanogenerators. Science. 2001;294:1537–1540
  81. Fracasso G, Bellisola G, Cingarlini S, et al.  Anti-tumor effects of toxins to the prostate specific membrane antigen. Prostate. 2002;53:9–23
  82. Ross S, Spencer SD, Holcomb I, et al.  Prostate stem cell antigen as therapy target: tissue expression and in vivo efficacy of an immunoconjugate. Cancer Res. 2002;2546–2553
  83. Schwaab T, Lewis LD, Cole BF, et al.  Phase I pilot trial of the biphasic antibody MDXH210 (anti-FcγRI X anti-Her-2/neu) in pateients whose prostate cancer overexpresses Her-2/neu. J. Immunother. 2001;24:79–87
  84. O’Donnell RT, DeNardo SJ, Yuan A, et al.  Radioimmunotherapy with -2IT-BAD-m170 for metastatic prostate cancer. Clin. Cancer Res. 2001;7:1561–1568
  85. O’Donnell RT, DeNardo SJ, Miers LA, et al.  Combined modality radioimmunotherapy for human prostate cancer xenografts with taxanes and 90yttrium-DOTA-peptide-ChL6. Prostate. 2002;50:27–37
  86. Murphy GP, Tjoa BA, Simmons SJ, et al.  Phase II prostate cancer vaccine trial: report of a study involving 37 patients with disease recurrence following primary treatment. Prostate. 1999;39:54–59
  87. Graves HC. Non-prostatic sources of prostate-specific antigen: a steroid hormone-dependent phenomenon?. Clin. Chem. 1995;41:7–9
  88. Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin. Cancer Res. 1997;3:81–85
  89. O’Keefe DS, Su SL, Bacich DJ, et al.  Mapping, genomic organization and promoter analysis of the human prostate-specific membrane antigen gene. Biochem. Biophys. Acta. 1998;1443:113–127
  90. Apostolopoulos V, McKenzie I. Cellular mucins: targets for immunotherapy. Crit. Rev. Immunol. 1994;14:293–309
  91. Ho SB, Niehans GA, Lyftogt C, et al.  Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 1993;53:641–651
  92. Van Ophoven , Tso CL, et al.  Recombinant vaccinia virus expressing MUC1/IL-2 genes for advanced prostate cancer: Basic biology and phase I trial. Proc. Am. Assoc. Cancer Res. 1999;40:1550
  93. Van Ophoven , Tso CL, et al.  Systemic immunotherapy of advanced prostate cancer: preliminary results of a phase I clinical trial using recombinant vaccinia virus encoding human MUC1 and interleukin-12 genes. Proc. Am. Soc. Clin. Oncol. 1999;18:1367
  94. Slovin SF, Livingston P, et al.  Targeted therapy in prostate cancer: vaccination with a glycoprotein MUC1-KLH-QS21 peptide conjugate. Proc. Am. Soc. Clin. Oncol. 1997;16:311
  95. Slovin SF, Scher HI. Peptide and carbohydrate vaccines in relapsed prostate cancer: immunogenicity of synthetic vaccines in man – clinical trails at Memorial Sloan Kettering Cancer Center. Semin. Oncol. 1999;26:448–454
  96. Price MR, Sekowski M, Ladanyi A, et al.  Immune recognition of human colonic tumor-associated MUC-2 mucins using an antipeptide antibody. Int. J. Cancer. 1993;55:753–759
  97. Gambus G, de Bolos C, Andreu D, Franci C, Egea G, Real FX. Detection of MUC2 apomucin tandem repeat with mouse monoclonal antibody. Gastroenterology. 1993;104:93–102
  98. Kim J, Park TK, Hu S, Abrampah K, Zhang S. Defining the molecular recognition of Globo H antigen through probe structures prepared by total synthesis. J. Organ. Chem. 1995;60:7716–7717
  99. Slovin SF, Ragupathi G, Adluri S, et al.  Carbohydrate vaccines in prostate cancer: immunogenicity of a fully synthetic Globo H hexasaccharide conjugate in man. Proc. Natl. Acad. Sci. USA. 1999;96:5710–5715
  100. Slovin SF, Livingston PO, et al.  Carbohydrate vaccines as immunotherapy for prostate cancer: Globo-H-KLH conjugate plus QS21. Proc. Am Soc. Clin. Oncol. 1998;17:433
  101. Helling F, Livingston PO. Ganglioside conjugate vaccines. Mol. Chem. Neuropathol. 1994;21:299–307
  102. Livingston PO. Augmenting the immunogenicity of carbohydrate tumor antigens. Semin. Cancer Biol. 1995;6:357–366
  103. Livingston PO, Adluri S, Helling F, et al.  Phase I trial of immunological adjuvant QS21 with a GM2 ganglioside-KLH conjugate vaccine in patients with malignant melanoma. Vaccine. 1994;12:1275–1280
  104. Shay JW, Wright WE. Telomerase: a target for cancer therapeutics. Cancer Cell. 2002;2:257–265
  105. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay JW. Telomerase activity in human germline and embryonic tissues. Dev. Genet. 1996;18:173–179
  106. Forsyth NR, Wright WE, Shay JW. Telomerase and differentiation in multicellular organisms: turn it off, turn it on, and turn it off again. Differentiation. 2002;69:188–197
  107. Adhuri S, Helling F, Ogata S, et al.  Immunogenicity of synthetic and TG- and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol. Immunother. 1995;41:184–192
  108. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392:245–252
  109. Blackburn EH. Structure and functions of telomeres. Nature. 1991;350:569–573
  110. Hodes RJ. Telomere length, aging, and somatic cell turnover. J. Exp. Med. 1999;190:153–156
  111. Weng NP, Hathcock KS, Hodes RJ. Regulation of telomere length and telomerase in T and B cells: a mechanism for maintaining replicative potential. Immunity. 1998;9:151–157
  112. Hiyama K, Hirai Y, Kyoizumi S, et al.  Activation of telomerase in human lymphocytes and hematopoietic progenitor cells. J. Immunol. 1995;155:3711–3715
  113. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur. J. Cancer. 1997;33:787–791
  114. Kim NW, Piatyszek MA, Prowse KR, et al.  Specific association of human telomerase activity with immortal cells and cancer. Science. 1994;266:2011–2015
  115. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673–679
  116. Minev B, Hipp J, Firat H, et al.  Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc. Natl. Acad. Sci. USA. 2000;97:4796–4801
  117. Nair SK, Heiser A, Boczkowski D, et al.  Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. Nat. Med. 2000;6:1011–1017
  118. Vonderheide RH. Telomerase as a universal tumor-associated antigen for cancer immunotherapy. Oncogene. 2002;21:674–679
  119. Heiser A, Maurice MA, Yancy DR, et al.  Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. J. Immunol. 2001;166:2953–2960
  120. Greener M. Telomerase: the search for a universal cancer vaccine. Mol. Med. Today. 2000;6:257
  121. Palucka K, Bancereau J. Dendritic cells: a link between innate and adaptive immunity. J. Clin. Immunol. 1999;19:12–25
  122. Timmerman JM, Levy R. Dendritic cell vaccines for cancer immunotherapy. Ann. Rev. Med. 1999;50:507–529
  123. Esumi N, Hunt B, Itaya T, Frost P. Reduced tumorigenicity of murine tumor cells secreting INF-γ is due to nonspecific host responses and is unrelated to class I major histocompatibility complex expression. Cancer Res. 1991;51:1185–1189
  124. Gansbacher B, Bannerji R, Daniels B, Zier K, Cronin K, Gilboa E. Retroviral vector-mediated INF-γ gene transfer into tumor cells generates potent and long lasting antitumor immunity. Cancer Res. 1990;50:7820–7825
  125. Dong Z, Greene G, Pettaway C, et al.  Suppression of angiogenesis, tumorigenicity, and metastasis by human prostate cancer engineered to produce interferon-β. Cancer Res. 1999;59:872–879
  126. Bulbul MA, Huben RP, Murphy GP. Interferon-β treatment of metastatic prostate cancer. J. Surg. Oncol. 1986;33:231–233
  127. Gutterman JU. Cytokine therapeutics: lessons from interferon-α. Proc Natl. Acad. Sci. USA. 1994;91:1198–1205
  128. Sica G, Fabbroni L, Castagnetta L, et al.  Antiproliferative effect of interferons on human prostate carcinoma cell lines. Urol. Res. 1989;17:111–115
  129. Saffran DC, Horton HM, Yankauckas MA, et al.  Immunotherapy of established tumors in mice by intra-tumoral injection of IL-2 plasmid DNA: induction of CD8+ T cell immunity. Cancer Gene Ther. 1998;5:321–330
  130. Kawakami Y, Haas GP, Lotze MT. Expansion of tumor-infiltrating lymphocytes from human tumors using the T-cell growth factors interleukin-2 and interleukin-4. J. Immunother. 1993;14:336–347
  131. Forni G, Giovarelli M, Santoni A. Lymphokine-activated tumor inhibition in vivo. The local administration of interleukin-2 triggers nonreactive lymphocytes from tumor bearing mice to inhibit tumor growth in vivo. J. Immunol. 1985;134:1305–1312
  132. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J. Exp. Med. 1990;172:1217–1224
  133. Bannerji R, Arroyo CD, Cordon-Cardo C, Gilboa E. The role of IL-2 secreted from genetically modified tumor cells in the establishment of antitumor immunity. J. Immunol. 1994;152:2324–2332
  134. Kaushik A. Leuvectin Vical Inc. Curr. Opin. Investig Drugs. 2001;2:976–981
  135. Hautman S, Huland E, Huland H. Intra-tumoral depot interleukin-2 therapy inhibits tumor growth in Dunning adenocarcinoma of the prostate implanted subcutaneously in rats. J. Cancer Res. Clin. Oncol. 1997;123:614–618
  136. Belldegrun A, Tso CL, Zisman A, et al.  Interleukin 2 gene therapy for prostate cancer: phase I clinical trial and basic biology. Hum. Gene Ther. 2001;12:883–892
  137. Hull GW, McCurdy MA, Nasu Y, et al.  Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin. Cancer Res. 2000;6:4101–4109
  138. Nasu Y, Bangma CH, Hull GW, et al.  Adenovirus-mediated interleukin 12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model. Gene Ther. 1999;6:338–349
  139. Sanford MA, Yan Y, Canfield SE, et al.  Independent contributions of GR-1+ leukocytes and Fas/FasL interactions to induce apoptosis following interkeukin-12 gene therapy in a metastatic model of prostate cancer. Hum. Gene Ther. 2001;12:1485–1498
  140. Dias S, Boyd R, Balkwill F. IL-12 regulates VEGF and MMPs in a murine breast cancer model. Int. J. Cancer. 1998;78:361–365
  141. Hiscox S, Hallett MB, Puntis MC, Jiang WG. Inhibition of cancer cell motility and invasion by interleukin-12. Clin. Exp. Metastasis. 1995;13:396–404
  142. Tagaya Y, Bamford RN, DeFilippis AP, Waldmann TA. IL-15: a pleiotropic cytokine with diverse receptor/signaling pathways whose expression is controlled at multiple levels. Immunity. 1996;4:329–336
  143. Mrozek E, Anderson P, Caligiuri MA. Role of interleukin-15 in the development of human CD56+ natural killer cells from CD 34+ hematopoietic progenitor cells. Blood. 1996;87:2632–2640
  144. Carson WE, Fehniger TA, Haldar S, et al.  A potential role for interleukin 15 in the regulation of human killer cell survival. J. Clin. Invest. 1997;99:937–943
  145. Hazama S, Noma T, Wang F, et al.  Tumor cells engineered to secrete interleukin 15 augment anti-tumor immune responses in vivo. Br. J. Cancer. 1999;80:1420–1426
  146. Lieschke GJ, Burgess AW. Granulocyte colony stimulating factor and granulocyte-macrophage colony-stimulating factor. N. Engl. J. Med. 1992;372:28–35
  147. Simons JW, Mikhak B, Chang JF, et al.  Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 1999;59:5160–5168
  148. Simmons SJ, Tjoa BA, Rogers M, et al.  GM-CSF as a systemic adjuvant in a phase II prostate cancer vaccine trial. Prostate. 1999;39:291–297

PII: S0305-7372(03)00005-7

doi: 10.1016/S0305-7372(03)00005-7

Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 199-209 , June 2003

Article Tools